Synchron Raises $200 Million in Series D to Advance Brain-Computer Interface Technology
Synchron has secured $200 million in its Series D funding round to accelerate the commercialization of its Stentrode™ brain-computer interface (BCI) platform. The investment will also strengthen the company’s artificial intelligence and engineering development teams in New York and San Diego.
Advancing the Stentrode™ Technology
The Stentrode™ is an endovascular electrode array designed to help people with severe paralysis control digital devices using only their thoughts. This funding will further support product refinement and early market deployment.
Photo Information
Media Contact
- Kimberly Ha
- Email: kha@synchron.com
- Organization: Synchron
“Funding will advance commercialization of the Stentrode™ BCI platform and expand AI and engineering operations in New York and San Diego.”
Author’s Summary: The $200 million investment marks a major milestone for Synchron as it moves closer to commercializing its thought-controlled Stentrode™ BCI and growing its U.S. engineering presence.